Endotelioand cardioprotective effects of HMG-Co-A reductase in endotoksininducing endotelial dysfunction

The use of inhibitors of HMG-Co-A reductase inhibitor simvastatin, atorvastatin, rosuvastatin and nanoparticulative rosuvastatin on background modeling endotoksininducing pathology, introduction of strain 603 Staphylococcusaureus leads to the development of dose-response endotelioprotectiv action, expressed in the normalization of QED, prevent increase adrenoreactivity and exhaustion of myocardial reserve and and normalization of biochemical markers of inflammation (C-reactive protein) and the level of proinflammatory cytokines. When this is detected positive dynamics and-products of NO and expression of eNOS.